ATF3 represses PDX-1 expression in pancreatic β-cells

Area of Science:

• Molecular Biology
• Endocrinology
• Diabetes Research

Background:

• PDX-1 expression is crucial for pancreatic beta cell function and its downregulation is implicated in type 2 diabetes.
• The specific molecular mechanisms and regulators responsible for PDX-1 downregulation remain incompletely understood.

Purpose of the Study:

• To investigate the role of Activating Transcription Factor 3 (ATF3) as a negative regulator of PDX-1 expression in pancreatic beta cells.
• To identify the specific binding site and mechanism by which ATF3 represses PDX-1 gene activity.

Main Methods:

• Utilized MIN6N8 pancreatic beta cell line for experiments.
• Performed promoter activity assays using 5' deletion reporters and site-directed mutagenesis.
• Conducted electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) assays.
• Treated cells with thapsigargin (ER stress inducer), high glucose, and high palmitate.

Main Results:

• ATF3 expression and ER stress induction by thapsigargin decreased PDX-1 expression and repressed PDX-1 promoter activity.
• ATF3 was found to bind directly to a specific region (-759 to -738) of the PDX-1 promoter containing an ATF/CRE site.
• Mutation of this ATF/CRE site abolished ATF3-mediated repression of PDX-1.
• Elevated glucose and palmitate levels increased ATF3 expression and decreased PDX-1 expression in beta cells.

Conclusions:

• ATF3 directly represses PDX-1 expression by binding to a specific element in its promoter.
• ATF3 mediates the downregulation of PDX-1 in response to hyperglycemia and hyperlipidemia.
• These findings highlight ATF3 as a key player in the suppression of pancreatic beta cell function and suggest its involvement in type 2 diabetes pathogenesis.